source
- Owkin and Servier partner to use AI platform K Pro for oncology discovery and trial designOwkin, an AI drug-discovery CRO, has entered a new agreement with French pharmaceutical company Servier to license its AI scientist, K Pro, for use in Servier’s oncology research and clinical trial…
- FDA grants three-month review extension for Exelixis' metastatic colorectal cancer candidateExelixis, a California drug developer, has provided the FDA with additional safety and efficacy data for its experimental therapy aimed at treating metastatic colorectal cancer. The agency respond…